Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

ItalyBack to Italy

Clinical trials in Cremona

58 clinical trials in Cremona, Italy. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Cremona at a glance
58
clinical trials
  • Paediatric trials0
  • Research sites0
Type of trial
Recruitment status
Quick filters

58 trials in Cremona

Open in trial search

Small cell lung cancer+2

Recruiting

Study of BNT327 with etoposide and carboplatin compared to atezolizumab with etoposide and carboplatin for patients with untreated extensive-stage small-cell lung cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:BioNTech SE

Squamous cell carcinoma of lung+6

Recruiting

Study on the Safety and Effectiveness of BNT327 with Chemotherapy for Patients with Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:BNT327
  • Sponsor:BioNTech SE

Oesophageal adenocarcinoma

Recruiting

Switch maintenance with paclitaxel, ramucirumab and tislelizumab versus continued chemotherapy with tislelizumab in HER2‑negative, PD‑L1‑positive gastroesophageal cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Fondazione GONO G.I.

Cardiac failure+1

Recruiting

Study of Zenagamtide (NNC0487-0111) versus placebo in patients with heart failure with preserved or mildly reduced ejection fraction and obesity

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Sponsor:Novo Nordisk A/S

Hormone-dependent prostate cancer

Recruiting

A study testing tulmimetostat with darolutamide or abiraterone in patients with metastatic hormone-sensitive prostate cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone
  • Sponsor:Novartis Pharma AG

Bacteraemia

Recruiting

Comparing piperacillin-tazobactam and meropenem for treating bloodstream infections caused by cephalosporin-resistant bacteria in adult patients

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Meropenem Anhydrous
  • Sponsor:Azienda Ospedaliero Universitaria Di Modena

Gastric cancer+3

Recruiting

Study of HLX22, Trastuzumab, and Chemotherapy for Patients with Advanced or Metastatic Stomach and Gastroesophageal Cancer

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Shanghai Henlius Biotech Inc.

Myelodysplastic syndrome

Recruiting

Study on Luspatercept for Treating Anemia in Patients with Myelodysplastic Syndromes (MDS) with del5q, Resistant to Prior Treatments and Needing Blood Transfusions

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Luspatercept
  • Sponsor:Associazione Qol-One

Pancreatic carcinoma

Recruiting

Study Comparing Gemcitabine and Paclitaxel with Drug Combination for Patients with Advanced Pancreatic Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Fondazione GONO G.I.

Acute myeloid leukaemia

Recruiting

Study of gemtuzumab ozogamicin with chemotherapy for adults aged 18-60 with newly diagnosed favorable-intermediate-risk acute myeloid leukemia

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Busulfan
  • Sponsor:Fondazione Gimema Franco Mandelli Onlus

Hormone-refractory prostate cancer+1

Recruiting

Study of PF-06821497 and Enzalutamide for Men with Advanced Prostate Cancer Resistant to Hormone Therapy

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Enzalutamide
  • Sponsor:Pfizer Inc.

Adenocarcinoma of colon

Recruiting

Study on Temozolomide and Irinotecan for Patients with Stage II/III Colorectal Cancer and Positive ctDNA After Chemotherapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Temozolomide
  • Sponsor:Fondazione IRCCS Istituto Nazionale Dei Tumori

Other cities in Italy

The busiest research cities in the country

All 237 cities in Italy

Clinical research in Cremona

What the registry says about research in the country

01 Lung Cancer Research

Multiple clinical trials focusing on non-small cell lung cancer are evaluating novel therapeutic approaches, including combination treatments with targeted therapies and immunotherapy agents.

  • Advanced NSCLC Treatment
  • Targeted Therapy Combinations
  • Biomarker-Driven Approaches

Studies are investigating treatments for patients with specific genetic mutations and exploring alternatives to traditional chemotherapy.

02 Gastrointestinal Oncology

Research in gastric and pancreatic cancers is exploring innovative combination therapies and maintenance treatments to improve patient outcomes.

  • Advanced Gastric Cancer
  • Pancreatic Adenocarcinoma
  • Novel Drug Combinations

Studies are evaluating both targeted therapies and immunotherapy approaches for these challenging cancers.

03 Genitourinary Cancers

Trials in prostate cancer and bladder cancer are investigating new treatment strategies, including hormone therapy combinations and immunotherapy approaches.

  • Metastatic Prostate Cancer
  • Urothelial Carcinoma
  • Novel Therapeutic Combinations

Research focuses on improving survival outcomes and quality of life for patients with advanced disease.

Back to ItalyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.